Streetbeat News

Analyst Ratings

ARMK

Truist Securities has maintained its Buy rating on Aramark and increased the price target from $37 to $42, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:44 am

EXAS

Piper Sandler analyst David Westenberg has maintained an Overweight rating on Exact Sciences (NASDAQ:EXAS) and raised the price target from $75 to $85.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:42 am

AMZN

Needham analyst Laura Martin has reiterated a Buy rating on Amazon.com (NASDAQ:AMZN) and maintained a price target of $210.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:41 am

KRNT

Needham analyst James Ricchiuti has reiterated a Buy rating on Kornit Digital (NASDAQ:KRNT) and maintained a price target of $27.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:39 am

DPZ

Baird analyst David Tarantino maintains an Outperform rating on Domino's Pizza (NYSE:DPZ) but lowers the price target from $580 to $535.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:38 am

HRMY

Needham analyst Ami Fadia has reiterated a Buy rating on Harmony Biosciences with a maintained price target of $52.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:37 am

MTSI

Benchmark analyst David Williams has reiterated a Buy rating on MACOM Technology Solutions (NASDAQ:MTSI) and maintained a price target of $120.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:32 am

MLTX

HC Wainwright & Co. has reiterated its Buy rating on MoonLake (NASDAQ:MLTX) and maintained a price target of $100, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:27 am

TIL

HC Wainwright & Co. has maintained a Buy rating on Instil Bio and raised the price target from $25 to $40, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:23 am

FEMY

HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on Femasys (NASDAQ:FEMY) and maintained a price target of $12.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:19 am